Online ISSN 2313-1519
Print    ISSN 1812-2892
Abstract - Determination of cytokine profile and fecal calprotectin in patients with inflammatory bowel disease of different activity degree
[PDF]           
Ainur Doszhan, Roza Bektayeva, Aiman Galiyeva, Kapura Adrissova

ABSTRACT

Aim: To determine the IL-6, IL-8, TNF-α and fecal calprotectin levels in different phases of the disease and correlate their values with the clinical and endoscopic data in patients with inflammatory bowel diseases.

Methods: 41 patients with IBD were selected: 78% with ulcerative colitis and 22% with Crohn's disease, 39% women and 61% men, mean age 35,3±1,9. Ulcerative colitis: acute current – 12,5%, chronic continuous – 6,25%, chronic relapsing – 62,5%, rarely relapsing – 12,5%, often relapsing – 6,25%. Minimal activity – 15,6%, moderate activity – 84,4%. Crohn's disease depending on the Crohn's Disease Activity Index (CDAI): mild disease and minimal activity – 55,6%, moderate severity and moderate activity – 44,4%.

Results: IL-6 was increased to 20,56±5,51 pg/ml at ulcerative colitis, to 18,64±4,70 pg/ml at Crohn's disease; IL-8 – 79,38±15,37 pg/ml at ulcerative colitis and 82,49±34,81 pg/ml at Crohn's disease; TNF-α – 28,70±3,24 pg/ml and 32,32±6,92 pg/ml, respectively. Depending on the extent of the lesion: for IL-6 at E2 – 23,91±14,64 pg/ml and at E3 – 20,54±5,61 pg/ml; for IL-8 at E2 – 60,95±14,60 pg/ml and at E3 – 97,31±24,10 pg/ml.

Conclusion: The results of the study have demonstrated an increase in the concentrations of IL-6, IL-8 and TNF-α in patients with ulcerative colitis and Crohn's disease, significantly exceeding the reference values. With increased activity of the inflammatory process, a significant raise in IL-6, IL-8 and TNF-α level was observed. Determining the level of fecal calprotectin depending on the location of the lesion and the activity of the process confirmed its importance in assessing the extent of lesions of the colon and diagnosing the activity of ulcerative colitis and Crohn's disease in different phases of the disease.

Key words: ulcerative colitis, Crohn's disease, cytokine profile, tumor necrosis factor, interleukins

Corresponding Author: Ainur Doszhan, Department of Gastroenterology and Infectious Diseases, Astana Medical University, Astana city, Republic of Kazakhstan. Tel.: 87017709708. E-mail: doszhan_88_88@mail.ru

 

References

1. Ng SC, Shi HY, Hamidi N, Underwood FE, Nang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, Sung JJY, Kaplan GG. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018; 390(10114):2769-2778. https://doi.org/10.1016/S0140-6736(17)32448-0

2. Guan Q, Zhang J. Recent Advances: The Imbalance of Cytokines in the Pathogenesis of Inflammatory Bowel Disease. Mediators of Inflammation. 2017; 2017:4810258.

https://doi.org/10.1155/2017/4810258

3. Ivashkin VT, Lapina TL. Gastroenterologiya. Natsional'noe rukovodstvo: kratkoe izdanie (National guideline: short edition) [in Russian]. GEOTAR-Media. 2015; 480.

4. Loddo IN, Romano CC. Inflammatory bowel disease: genetics, epigenetics, and pathogenesis. Frontiers in Immunology. 2015; 6:551. https://doi.org/10.3389/fimmu.2015.00551

5. Neurath MF. Cytokines in inflammatory bowel disease. Nature Reviews Immunology. 2014; 14(5):329-342. https://doi.org/10.1038/nri3661

6. Souza HS, Fiocchi CV. Immunopathogenesis of IBD: current state of the art. Nature Reviews Gastroenterology & Hepatology. 2016; 13(1):13-27. https://doi.org/10.1038/nrgastro.2015.186

7. Takać B., Mihaljević S., Śtefanić M., Glavaš-Obrovac L., Kibel A., Samardžija M. Importance of Interleukin 6 in Pathogenesis of Inflammatory Bowel Disease. Coll. Antropol. 2014; 38(2): 659-664.

8. Locksley RM, Killeen NN, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001; 104:487-501. https://doi.org/10.1016/S0092-8674(01)00237-9

9. Műzes GM, Molnár BN, Tulassay ZF. Changes of the cytokine profile in inflammatory bowel diseases. World Journal of Gastroenteroly. 2012; 18(41):5848-5861. https://doi.org/10.3748/wjg.v18.i41.5848

10. Murch SR, Braegger CD, Walker-Smith JA, MacDonald T. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut. 1993; 34:1705-1709.
https://doi.org/10.1136/gut.34.12.1705

11. Cotton JA, Platnich JM, Muruve DA, Jijon HB, Buret AG, Beck PL. Interleukin-8 in gastrointestinal inflammation and malignancy: induction and clinical consequences. International Journal of Interferon, Cytokine and Mediator Research. 2016; 8:13-34. https://doi.org/10.2147/IJICMR.S63682

12. Ljuca F, Gegic A, Salkic NN, Pavlovic-Calic N. Circulating cytokines reflect mucosal inflammatory status in patients with Crohn's disease. Digestive Diseases and Science. 2010; 55(8):2316-26. https://doi.org/10.1007/s10620-009-1016-9

13. Nancey S, Hamzaoui N, Moussata D, Graber I, Bienvenu J, Flourie B. Serum interleukin-6, soluble interleukin-6 receptor and Crohn's disease activity. Digestive Diseases and Science. 2008; 53(1):242-7. https://doi.org/10.1007/s10620-007-9849-6

14. Vrabie R, Kane S. Noninvasive Markers of Disease Activity in Inflammatory Bowel Disease. Gastroenterology & Hepatology. 2014; 10(9):576-584.

15. Matusiewicz M, Neubauer K, Bednarz-Misa I, Gorska S, Krzystek-Korpacka M. Systemic interleukin-9 in inflammatory bowel disease: Association with mucosal healing in ulcerative colitis. World J Gastroenterol. 2017; 23(22):4039-4046. https://doi.org/10.3748/wjg.v23.i22.4039

16. Magro F., Gionchetti P., Eliakim R. et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. Journal of Crohn's and Colitis. 2017; 649-670. https://doi.org/10.1093/ecco-jcc/jjx008

17. Gomollón F., Dignass A., Annese V. et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. Journal of Crohn's and Colitis. 2017; 3-25. https://doi.org/10.1093/ecco-jcc/jjw168

18. Ivashkin VT, Shelygin YA, Abdulganieva D I, Abdulkhakov RA, Alekseeva O P, Achkasov SI et al. Rekomendatsii Rossiiskoi gastroenterologicheskoi assotsiatsii i Assotsiatsii koloproktologov Rossii po diagnostike i lecheniyu vzroslykh bol'nykh yazvennym kolitom (Guidelines of the Russian Gastroenterological Association and the Association of Coloproctologists for diagnosis and treatment of adults with ulcerative colitis) [in Russian]. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii. 2015; 1:48-65.

19. Konovich EA, Shirokih KE, Halif IL, Shapina MV. Citokiny tolstoj kishki pri tjazheloj forme jazvennogo kolita (The colon cytokines at acute ulcerous colitis) [in Russian]. Novosti koloproktologii. 2016; 1:93-98.

 

Volume 2, Number 52 (2019)